Electra Therapeutics, Inc.
Nasdaq · Biological Products, (No Diagnostic Substances)
Company Overview
A concise company profile alongside the latest public filing activity.
Electra Therapeutics is a biotechnology company developing antibody-based therapies targeting the immune protein LILRB2 for autoimmune and inflammatory diseases, and CD200R1 for autoimmune conditions. The company is based in South San Francisco, CA.
Company profile sourced from SEC filings.
Corporate Insider Trades
Open-market purchases and sales by directors, officers, and other company insiders.
| Insider | Type | Value | Shares / Price | Date |
|---|---|---|---|---|
| ORBIMED ADVISORS LLCDirector | Buy | $191K | 24,313at $7.84 | Nov 3, 2026 |
| ORBIMED ADVISORS LLCDirector | Buy | $767K | 97,800at $7.84 | Nov 3, 2026 |
| ORBIMED ADVISORS LLCDirector | Buy | $192K | 24,400at $7.88 | Nov 3, 2026 |
| ORBIMED ADVISORS LLCDirector | Buy | $777K | 98,600at $7.88 | Nov 3, 2026 |
| ORBIMED ADVISORS LLCDirector | Buy | $72K | 9,267at $7.78 | Nov 4, 2026 |
| ORBIMED ADVISORS LLCDirector | Buy | $289K | 37,100at $7.78 | Nov 4, 2026 |
| ORBIMED ADVISORS LLCDirector | Buy | $35K | 5,000at $7.07 | Nov 4, 2026 |
| ORBIMED ADVISORS LLCDirector | Buy | $141K | 20,000at $7.07 | Nov 4, 2026 |
| ORBIMED ADVISORS LLCDirector | Buy | $226K | 30,891at $7.31 | Nov 5, 2026 |
| ORBIMED ADVISORS LLCDirector | Buy | $915K | 125,200at $7.31 | Nov 5, 2026 |
| GORDON CARL LDirector | Buy | $191K | 24,313at $7.84 | Nov 3, 2026 |
| GORDON CARL LDirector | Buy | $767K | 97,800at $7.84 | Nov 3, 2026 |
| GORDON CARL LDirector | Buy | $192K | 24,400at $7.88 | Nov 3, 2026 |
| GORDON CARL LDirector | Buy | $777K | 98,600at $7.88 | Nov 3, 2026 |
| GORDON CARL LDirector | Buy | $72K | 9,267at $7.78 | Nov 4, 2026 |
| GORDON CARL LDirector | Buy | $289K | 37,100at $7.78 | Nov 4, 2026 |
| GORDON CARL LDirector | Buy | $35K | 5,000at $7.07 | Nov 4, 2026 |
| GORDON CARL LDirector | Buy | $141K | 20,000at $7.07 | Nov 4, 2026 |
| GORDON CARL LDirector | Buy | $226K | 30,891at $7.31 | Nov 5, 2026 |
| GORDON CARL LDirector | Buy | $915K | 125,200at $7.31 | Nov 5, 2026 |
Source: SEC EDGAR Form 4 filings
Congressional Trades
Recent disclosures by members of the U.S. House and Senate.
Source: Senate eFD and House Clerk STOCK Act disclosures
Get notable ETRA activity by email
Free alerts for the insider and congressional trades worth watching.
For informational purposes only, not investment advice. Filings can be delayed, corrected, or amended. Trading activity alone does not predict future performance.